Triazolone PPARα Antagonists for Selective Cancer Metabolic Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments often target energy metabolism of cancer cells inefficiently, as they rely on aerobic glycolysis rather than oxidative phosphorylation, leading to challenges in selectively inhibiting cancer cell proliferation and survival.
Innovation Solution
Development of compounds that act as selective PPARα antagonists to inhibit fatty acid oxidation in cancer cells, which are particularly effective in treating cancers like prostate, breast, colon, and pancreatic cancers, as well as viral infections such as HCV and HIV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-cancer agents are administered, then cancer treatment is achieved, but chemotoxicity to healthy cells remains high
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target cancer cells exhibiting the Warburg effect (aerobic glycolysis) while sparing normal cells. The selective PPARα antagonists and FAO inhibitors are engineered to exploit the unique metabolic phenotype of cancer cells, delivering toxic effects locally to cancer cells rather than causing systemic chemotoxicity to healthy tissues.
Solution Approach 2:
The patent employs parameter changes by targeting the metabolic parameters of cancer cells - specifically the shift from oxidative phosphorylation to aerobic glycolysis. By developing inhibitors that interfere with fatty acid oxidation and glycolytic pathways, the treatment exploits the altered metabolic state of cancer cells to achieve selective toxicity based on metabolic parameter differences between cancer and normal cells.
2Productivity
If PPARα antagonists are used to inhibit fatty acid oxidation, then cancer cell proliferation is reduced, but selectivity against normal cells must be maintained
Solution Approach 1:
The patent converts the harmful overreliance on fatty acid oxidation in cancer cells into a therapeutic benefit. By designing selective PPARα antagonists that specifically inhibit FAO in cancer cells with high PPARα expression and Warburg effect, the treatment transforms the cancer cells' metabolic dependency into their vulnerability, achieving proliferation inhibition while maintaining selectivity through the unique metabolic signature of cancer cells.
3Productivity
If mitochondrial uncoupling is induced to promote glycolysis, then cancer cell metabolism is disrupted, but energy depletion must be avoided in healthy cells
Solution Approach 1:
The patent applies preliminary action by first identifying and selecting cancer cells with specific metabolic characteristics (Warburg effect, high PPARα expression, reliance on FAO) before administering the selective inhibitors. This preliminary identification ensures that the metabolic disruption and energy depletion effects are concentrated in cancer cells that are already primed for such interference, while healthy cells with normal metabolism are spared from significant energy depletion.
Data Source
AI summary
The invention disclosed herein is directed to compounds of Formula Iand pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.